As the year comes to a close, we are still extremely busy liaising with the NHS, medical professionals, and pharmaceutical companies to support our day-to-day work for HAE patients and their families.

We have worked closely with pharmaceutical companies, supporting new medications going through clinical trials and licensing/approval. Overall, the arrival of these new medications in 2025 and 2026 holds great promise for enhancing patient care and contributing to better health outcomes for HAE patients in the UK.

New regulations from NHS England are currently in progress, specifically aimed at collaboration with the Rare Disease Network. We hope this initiative will lead to earlier detection and more accurate diagnosis. The anticipated outcome of these efforts is to improve the overall healthcare journey of those affected by Hereditary Angioedema, ultimately resulting in better treatment and care.

An increasing amount of effort is being dedicated to expanding the scope of research and data collection of both HAE-Normal C1 and Acquired Angioedema to help establish diagnosis and treatment. We have been supporting this research as much as possible because we are having an increasing number of patients with these types of angioedema reaching out to us for advice and support.

We recently completed a nationwide mailout campaign, sending letters and posters about HAE to every GP practice in the UK. The letters explained the condition, and the posters were intended for display in patient waiting areas. The goal was to raise awareness of HAE among both healthcare providers and the general public, and also with the hope of reaching those who may be undiagnosed.

We look forward to an exciting and productive 2025 and wish you all good health and happiness.